SEC Form 4 · accession 0000899243-17-024245

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Wilson Wai-Shun Cheung

Officer — CFO & Senior VP, Finance

Period of report

Oct 13, 2017

Accepted (ET)

Oct 16, 2017 · 5:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000880771

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Oct 13, 2017	M	52,000	—	A	69,158	D
Common Stock^F2	Oct 13, 2017	A	75,000	$0.00	A	144,158	D
Common Stock	Oct 13, 2017	D	144,158	$11.18	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Non-Qualified Stock Option (right to buy)^F3,F5,F4	$5.97	Oct 13, 2017	D	9,375	D	—	Aug 9, 2023	Common Stock	9,375	D
Non-Qualified Stock Option (right to buy)^F3,F5,F6	$4.52	Oct 13, 2017	D	24,792	D	—	Mar 14, 2024	Common Stock	24,792	D
Incentive Stock Option (right to buy)^F3,F5,F7	$8.83	Oct 13, 2017	D	39,225	D	—	Mar 16, 2025	Common Stock	39,225	D
Restricted Stock Unit^F3,F1,F8	—	Oct 13, 2017	M	6,000	D	—	—	Common Stock	6,000	D
Non-Qualified Stock Option (right to buy)^F3,F5,F7	$8.83	Oct 13, 2017	D	44,775	D	—	Mar 16, 2025	Common Stock	44,775	D
Restricted Stock Unit^F3,F1,F8	—	Oct 13, 2017	M	25,000	D	—	—	Common Stock	25,000	D
Incentive Stock Option (right to buy)^F11,F5,F9	$9.12	Oct 13, 2017	D	11,131	D	—	Mar 15, 2026	Common Stock	11,131	D
Non-Qualified Stock Option (right to buy)^F11,F5,F9	$9.12	Oct 13, 2017	D	72,869	D	—	Mar 15, 2026	Common Stock	72,869	D
Restricted Stock Unit^F11,F1,F8	—	Oct 13, 2017	M	9,000	D	—	—	Common Stock	9,000	D
Restricted Stock Unit^F11,F1,F8	—	Oct 13, 2017	M	12,000	D	—	—	Common Stock	12,000	D
Incentive Stock Option (right to buy)^F11,F5,F10	$9.65	Oct 13, 2017	D	10,651	D	—	Mar 8, 2027	Common Stock	10,651	D
Non-Qualified Stock Option (right to buy)^F11,F5,F10	$9.65	Oct 13, 2017	D	73,349	D	—	Mar 8, 2027	Common Stock	73,349	D

Explanation of responses

F1Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
F10Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
F11Granted under Issuer's 2015 Equity Incentive Plan.
F2Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
F3Granted under Issuer's 2005 Equity Incentive Plan.
F4Under its terms the option became exercisable in installments with 25% vesting on August 9, 2014 and 2.0833% vesting each month thereafter until it became vested in full on August 9, 2017.
F5The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F6Under its terms the option became exercisable in installments with 25% vesting on March 14, 2014 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2017.
F7Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
F8Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
F9Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.